Compare relapse clinical severity , post-relapse residual disability , and the probability of confirmed complete recovery from relapse between patients who relapsed during natalizumab ( n = 183/627 [ 29 % ] ) and placebo ( n = 176/315 [ 56 % ] ) treatments in the AFFIRM trial .